KRRO
Korro BioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The post-earnings company update kept the central upside case intact: KRRO-121 is still guided to a second-half 2026 regulatory filing, the AATD program remains on track for a second-quarter 2026 development-candidate nomination, a third GalNAc-conjugated program nomination is targeted for the second half of 2026, and management says the balance sheet can fund operations into the second half of 2028 [#8-K-2026-05-07][#10-Q-2026-05-07].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +13.5.
What can break
Even with runway improved into the second half of 2028, management says additional capital may still be required over time to fund development, manufacturing, and commercialization efforts [#10-Q-2026-05-07].
Momentum
52
Value
41
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $18.00 · Bear $8.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $19.82
Why
Momentum52 · Δ7d +0.7
Value41 · Δ7d +0.0
Sentiment59 · Δ7d +13.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
52
26% active weight
Current posture
7d trendSoftening
Δ7d
+0.7
Δ21d
+7.3
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
59
34% active weight
Current posture
7d trendImproving
Δ7d
+13.5
Δ21d
+1.9
Why this grade
Composite grade C. Momentum 52.4 / Value 41.1 / Sentiment 58.8
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$165.86M
Beta
2.98
Shares Out
14.42M
P/E (TTM) · Derived
-0.9
P/S (TTM)
10.22
P/FCF (TTM) · Derived
-1.60
Rev YoY
-100.0%
EPS YoY
-32.1%
Gross Margin
+10.8%
Op Margin
-1282.0%
Net Debt
-$32.67M
Current Ratio
8.13
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology